Pfizer, Inc. (PFE) Stock Rating Lowered by Credit Suisse Group
Pfizer, Inc. (NYSE:PFE) was downgraded by analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a research report issued on Thursday, Marketbeat Ratings reports. They presently have a $36.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $38.00. Credit Suisse Group’s price target suggests a potential upside of 7.33% from the company’s previous close.
Several other research firms have also weighed in on PFE. Sanford C. Bernstein reiterated a “buy” rating and set a $35.00 price objective on shares of Pfizer in a research note on Friday, March 24th. Barclays PLC reiterated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Wednesday, May 3rd. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 10th. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price objective on shares of Pfizer in a research note on Thursday, April 27th. Finally, ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $37.68.
Pfizer (PFE) traded down 0.24% during trading on Thursday, hitting $33.54. The company had a trading volume of 16,954,528 shares. Pfizer has a 12 month low of $29.83 and a 12 month high of $37.39. The company’s 50 day moving average price is $33.17 and its 200-day moving average price is $33.25. The company has a market cap of $200.16 billion, a PE ratio of 28.23 and a beta of 1.01. Pfizer also was the target of some unusual options trading activity on Tuesday. Stock investors purchased 21,983 put options on the company. This represents an increase of approximately 351% compared to the average volume of 4,871 put options.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The business had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The company’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.67 EPS. Equities analysts expect that Pfizer will post $2.55 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Pfizer, Inc. (PFE) Stock Rating Lowered by Credit Suisse Group” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/20/pfizer-inc-pfe-stock-rating-lowered-by-credit-suisse-group.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. D Orazio & Associates Inc. boosted its position in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the period. Northstar Group Inc. boosted its position in Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 35 shares during the period. Stone House Investment Management LLC boosted its position in Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 66 shares during the period. Naples Global Advisors LLC boosted its position in Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after buying an additional 79 shares during the period. Finally, Pure Financial Advisors Inc. boosted its position in Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 84 shares during the period. Institutional investors and hedge funds own 69.95% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.